New & Notable
Lilly's triple agonist led to high weight loss, reduced knee pain
Eli Lilly's 'triple-G' agonist led to an average weight loss of up to 28.7% and knee pain relief in a late-phase trial, but caused a rare, neurological side effect in some patients.
FDA approves first drug in National Priority Voucher program
The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two decades ago.
— BioPharma Dive
Structure announces mid-stage data for its oral GLP-1 candidate
Structure Therapeutics reported a placebo-adjusted weight loss of up to 15.3% for its oral GLP-1 drug candidate, aleniglipron, in a high-dose, exploratory phase 2 analysis.
Ascletis announces phase 2 data for its oral GLP-1 candidate
China's Ascletis Pharma reported a 7.7% placebo-adjusted weight loss for the highest dose of its oral GLP-1 drug candidate, ASC30, in a U.S.-based, phase 2 trial.
UK agrees to boost drug prices to dodge US pharma tariffs
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Consumer confusion fuels risky online drug purchases, survey finds
Due to widespread misunderstandings, many U.S. adults are buying drugs, especially GLP-1 products, from online, unlicensed sellers, a new survey reveals.
-
Wegovy linked to liver health benefits at low levels of weight loss
Wegovy may improve liver injury and scarring in adults with MASH and moderate-to-severe fibrosis, even without significant weight loss, data shows.
-
FDA expands the National Priority Voucher program to oral GLP-1s
The FDA's second wave of National Priority Voucher recipients includes Novo Nordisk and Eli Lilly's oral GLP-1s, expanding the list to 15 products.
-
Lilly advances amylin obesity drug eloralintide to phase 3 trials
Eli Lilly is set to begin late-stage clinical trials of its investigational amylin obesity drug next month, after encouraging phase 2 study results.
-
Top 10 metro areas for manufacturing biologics in 2026
Raleigh ranks as the top U.S. metro for biologics manufacturing investment in 2026, amid skilled labor shortages and shifting federal policies, a new report finds.
-
Innovent, Lilly's mazdutide outdoes Novo's semaglutide in phase 3 trial
Innovent Biologics and Eli Lilly's dual GLP-1/glucagon agonist, mazdutide, beats Novo Nordisk's semaglutide in a phase 3 trial of adults with diabetes and obesity.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.